GLP-1semaglutidealzheimersnovo nordiskevoke

Cummings and Scheltens dissect negative evoke trials of semaglutide in Alzheimer's

Two years of 14 mg semaglutide produced no clinical benefit in early Alzheimer's despite a robust drop in high-sensitivity C-reactive protein.

By Maren Holt · Senior Reporter, GLP-1

Sep 23 20:00 ETSource: The journal of prevention of Alzheimer's disease

The wire

01The review of evoke and evoke+ reports no clinical benefit from 14 mg oral semaglutide over two years, with CSF YKL-40 and GFAP reduced only 7% to 10% and no correlation with disease progression.
02The negative result undercuts observational signals that GLP-1s lower dementia incidence in type 2 diabetes, and argues peripheral inflammation reduction alone does not alter biomarker-confirmed Alzheimer's.
03Authors say enriching for elevated peripheral inflammation markers or using brain-penetrant GLP-1 receptor agonists could still yield benefit; this is commentary on completed trials, not new data.

From the source

Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications
The journal of prevention of Alzheimer's disease · 2026 Sep 24 · Cummings JL, Scheltens P et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42785112/